Widely Used COPD Meds Tied to Increased Fracture Risk
Authors: Pothirat C, Phetsuk N, Liwsrisakun C, Bumroongkit C, Deesomchok A, Theerakittikul T Abstract Objective: To identify the prevalence, clinical characteristics, disease severity, and correlations of major chronic respiratory diseases (CRDs) among the adult population living in Chiang Mai. Material and Method: A cross-sectional study was conducted with adults living in municipal areas of Chiang Mai. All clinical relevant data collected by face-to-face interview was confirmed by pulmonologists. The chest radiographic findings and post-bronchodilator spirometry were done in all subjects. The aeroallergen ski...
In this study, we investigate mitochondrial energetics and mtDNA methylation in senescent cells, and evaluate the potential of humanin and MOTS-c as novel senolytics or SASP modulators that can alleviate symptoms of frailty and extend health span by targeting mitochondrial bioenergetics. Exercise versus the Hallmarks of Aging https://www.fightaging.org/archives/2018/06/exercise-versus-the-hallmarks-of-aging/ The paper I'll point out today walks through the ways in which exercise is known to beneficially affect the Hallmarks of Aging. The Hallmarks are a list of the significant causes of aging that I dis...
Conclusions: Serological testing suggested that infection by atypical pathogens during AECOPD was relatively uncommon. In addition, PCR provided no direct evidence of infection by atypical pathogens. Thus, atypical pathogens may not be a major cause of AECOPD in South Korea. PMID: 29929350 [PubMed - as supplied by publisher]
Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive and incurable disease with limited overall survival. Nintedanib is a multikinase inhibitor, and its efficacy on IPF was demonstrated in phase III trials. However, a discrepancy exists between forced vital capacity (FVC) and patient-reported outcomes during nintedanib treatment. Accordingly, we retrospectively analyzed the effects of nintedanib on FVC and patient-reported outcomes among 25 IPF patients. Patient-reported outcomes were evaluated with modified medical research council (mMRC) grade and COPD assessment test (CAT) score. The changes in mMRC gr...
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Common in COPD are acute exacerbations (AE-COPD) that cause acute dyspnea, cough, and bronchospasm. Symptoms of AE-COPD mimic pulmonary embolism (PE).
We thank Drs. Takir and Esquinas for their interest in our research . In our paper we described an open-loop decision support system that is intended to assist the clinician in setting pressure support, evaluated in a mixed population of patients not currently anticipating weaning. We understand that distinct patient diagnoses has specific needs, to accommodate individual needs, the DSS has modes of operation that can be chosen by the clinician. Due to the limited sample size of the study there is insufficient data to draw conclusions about its operation on COPD patients with chronic respiratory failure.
Conclusion: OPC supplementation was effective in increasing the antioxidant capacity, in addition to improving the lipid profiles in patients with COPD.
Publication date: July 2018 Source:The Lancet Respiratory Medicine, Volume 6, Issue 7 Author(s): The Lancet Respiratory Medicine
We report improved lung function and quality of life following daily use of guaifenesin/dextromethorphan (Mucinex DM®, Reckitt Benckiser) for the treatment of mucus-related symptoms in a patient with COPD, who presented with increasing dyspnea, progressive cough and chest congestion.
Lara Muralt, Michael Furian, Mona Lichtblau, Sayaka S. Aeschbacher, Ross A. Clark, Bermet Estebesova, Ulan Sheraliev, Nuriddin Marazhapov, Batyr Osmonov, Maya Bisang, Stefanie Ulrich, Tsogyal D. Latshang, Silvia Ulrich, Talant M. Sooronbaev, Konrad E. Bloch